-
Will Senate Recess Without Approving Zika Funding Amid Mosquito Season?
Wednesday, June 29, 2016 - 2:19pm | 395Read More...Congressional Republicans proposed a Zika-virus funding package valued at $1.1 billion that was ultimately blocked by Democrats and shot down. A vote failed 52 to 48 to advance the legislation. According to the Washington Post, the bill contained politically motivated language against Planned...
-
Barclays On Popular Bank: 'Island Life Can Be Tough Sometimes'
Thursday, June 23, 2016 - 10:03am | 294Read More...Given Popular Inc (NASDAQ: BPOP)'s excess capital and valuation discount to U.S. peers, Barclays’ Matthew J. Keating believes the stock offers an “interesting” intermediate term investment option. Keating initiated coverage of Popular with an Equal-Weight rating and price target...
-
FDA Approves Use Of Zika Virus Blood Screener From Hologic And Grifols
Monday, June 20, 2016 - 4:55pm | 123Read More...Hologic Inc (NASDAQ: HOLX) and Grifols, S.A. (NASDAQ: GRFS) announced Monday that they won FDA approval for the use of the Procleix Zika virus blood screening assay. U.S. blood centers will use Procleix to screen blood donations in the Southern US and other areas potentially affected by the...
-
Bill And Melinda Gates Foundation Teams With Private Sector To Fight Zika
Saturday, June 11, 2016 - 3:38pm | 344Read More...Bill and Melinda Gates Foundation have partnered with the private sector to fight Zika amid the World Health Organization (WHO) warnings that people living in Zika-affected nations to delay pregnancy due to the virus' potential impact on children, according to a report on Fox Business Network. "I...
-
Intrexon, Inovio, Cerus Tick Higher Following President Obama's Zika Comments
Friday, May 20, 2016 - 1:03pm | 337Read More...The U.S. House of Representatives approved a new Republican-backed bill on Wednesday that aims to combat the Zika virus. While the bill would provide $622 million to fight the virus, the dollar amount is actually less than one-third of what President Barack Obama was previously seeking....
-
This Stock Is Winning From Brazil's Approval Of Genetically Engineered Mosquitoes
Wednesday, April 13, 2016 - 4:35pm | 310Read More...Shares of Intrexon Corp (NYSE: XON) surged as much as 9 percent after its Oxitec unit won a temporary approval from Brazil's Health Agency Anvisa to deploy its genetically engineered mosquito, OX513A, throughout the country. In a press release, Oxitec said its OX513A biologically controls...
-
Americans Don't Really Understand The Zika Virus
Wednesday, March 30, 2016 - 1:59pm | 368Read More...A new Harvard poll has found that the majority of Americans are misinformed about the risks of Zika virus, and sizable minority mistakenly believe that Zika virus is transmitted by coughing and sneezing. About one in five (22 percent) are not aware that Zika virus can be transmitted from mother...
-
Zika Concerns Raise Social Chatter For Birth Control; Teva Likely To Benefit
Thursday, March 10, 2016 - 10:55am | 341Read More...The latest data from TickerTags provides some unique insight into the fears the Zika virus outbreak is causing around the world. TickerTags monitors social media sites to identify trends by searching for words or phrases that appear together in social media content, such as tweets. Back in early...
-
Thermo Fisher To Offer Anti-Zika Virus Test Kits, Notes First Tests Available In US
Tuesday, February 23, 2016 - 8:51am | 202Read More...Thermo Fisher Scientific Inc. (NYSE: TMO) announced on Monday that it is now offering consumers a test kit to enable detection of the Zika virus in research applications. Thermo Fisher noted that its test is the first of its kind available in the US. The company added that its test also enables...
-
Inovio Reports Encouraging Results From Preclinical Testing Of Zika Virus Vaccine
Wednesday, February 17, 2016 - 11:52am | 253Read More...Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO) were trading higher by more than 5 percent on Wednesday after the company announced that preclinical testing of SynCon, a vaccine for the Zika virus, induced "robust and durable immune responses." Inovio is developing a vaccine for...
-
Intrexon Can Make Hundreds Of Millions From Zika Virus Treatment
Wednesday, February 17, 2016 - 10:12am | 313Read More...Intrexon Corp (NYSE: XON) shares have been volatile in recent months and are down 36 percent since August 17. Wunderlich’s Rob Breza maintained a Buy rating for the company, with a price target of $50. Intrexon’s efforts to set up a facility to combat the Zika virus and...
-
Monsanto Dispels Rumors It's Connected To Zika Virus, Notes 'Misinformation Causes Unwarranted Fear'
Tuesday, February 16, 2016 - 3:36pm | 215Read More...Monsanto Company (NYSE: MON) dispelled rumors that the company is linked to Zika virus and microcephaly. According to Monsanto's blog post, linking the company to the virus outbreak is simply "misinformation" and "causes unwarranted fear and distracts from the health crisis." Monsanto appears to be...
-
Zika Virus Spreading: Here's How To Play It Again
Wednesday, February 10, 2016 - 2:49pm | 355Read More...Reports continue to surface of confirmed Zika virus cases outside of the primary infection regions. China has now confirmed the first case of Zika in the world’s most populated country. The 34-year-old infected male had recently returned from a trip to Venezuela, a nation that may now have...
-
How Does The Zika Virus Affect U.S. Regulatory Approval Of ChemChina-Syngenta Deal?
Thursday, February 4, 2016 - 12:22pm | 175Read More...According to a report by the New York Post, the recent outbreak of the Zika virus could complicate the $43 billion merger between ChemChina and Syngenta AG (ADR) (NYSE: SYT). The New York Post noted that Syngenta "could be in a position" to create a product to deal with the Zikua...
-
EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, Ready For Phase 1 Study By Q4
Friday, January 29, 2016 - 2:38pm | 454Read More...Inovio Pharmaceuticals Inc (NASDAQ: INO) plans to complete its testing of a Zika vaccine in mice and monkeys by the third quarter of this year before moving to a Phase 1 study in Q4, a company spokesperson told Benzinga. The company said it plans to produce between 5,000 and 10,000 doses by Q3...
